In 2021, a comprehensive meta-analysis was conducted, classifying patients into five subgroups based on symptoms caused by drug therapy (gastrointestinal disturbances, chemotherapy-induced peripheral neuropathy, joint pain associated with aromatase inhibitors, joint symptoms associated with aromatase inhibitors, and cognitive impairments). Here, CYP19A1 is linked to peripheral neuropathy.